{
    "Trade/Device Name(s)": [
        "Optilite IgM Kit"
    ],
    "Submitter Information": "The Binding Site Group Ltd.",
    "510(k) Number": "K191635",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082129"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFN"
    ],
    "Summary Letter Date": "June 13, 2019",
    "Summary Letter Received Date": "June 19, 2019",
    "Submission Date": "July 4, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, And E Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgM"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Binding Site Optilite analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Quantitative immunoturbidimetry",
        "Turbidimetric"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Optilite IgM Kit, a quantitative immunoturbidimetric assay for IgM measurement using the Optilite analyser",
    "Indications for Use Summary": "Intended for quantitative in vitro measurement of IgM in human serum, lithium heparin or EDTA plasma to aid in diagnosis of abnormal protein metabolism and immune function, used with other clinical and laboratory findings",
    "fda_folder": "Immunology"
}